Lyon

• GRAALL2014 Recruiting
  2024-516103-16-00 4 2015-12-04 Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
• SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependym … Recruiting
  2024-512222-28-00 10 2015-06-02 Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
• rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma Recruiting
  2024-516078-31-00 10 2015-05-05 Recurrent and Primary Refractory Ewing Sarcoma
• A Phase I/II trial of MK-3475 (pembrolizumab) in children's solid tumors and lymphoma Recruiting
  2022-501257-36-00 9 2015-03-19 Treatment of advanced melanoma, or advanced, relapsed or refractory PD
• Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication: BIOMEDE 2.0 Recruiting
  2023-506027-29-00 5 2014-10-01 Children, adolescents and adults with newly diagnosed diffuse intrinsi
• MOST Plus (My Own Specific Treatment) - A two-period, multicenter, randomized, open-label, phase II study evaluating the clinical benefit of … Recruiting
  2023-510566-27-00 4 2014-02-27 Advanced / Metastatic cancers
• MEMMAT - Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial Recruiting
  2024-515626-92-00 4 2013-10-18 recurrent/progressive medulloblastoma, ependymoma and atypical teratoi
• GASTRICHIP TRIAL. D2 resection and HIPEC (Hyperthermic IntraPeritoneal Chemoperfusion) in locally advanced gastric carcinoma. Recruiting
  2024-516358-23-00 5 2013-06-24 Gastric adenocarcinoma
• Conservative treatment of patients with retinoblastoma Recruiting
  2024-517275-21-00 4 2012-02-20 Retinoblastoma
• Hyperthermic Intraperitoneal Chemotherapy in the treatment of Ovarian Cancer relapse Recruiting
  2024-517390-24-00 5 2011-04-26 Ovarian epithelial cancer : intraperitoneal resectable relapse
• PEHRICCA : PErioperative CISGEM plus RILVEGOSTOMIG in High-Risk resectable Intrahepatic CholangioCarcinoma Ended recruitment
  2025-521302-17-00 10 2026-05-26 Hihg risk of cholangiocarcinoma intra hépatic resectable
• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended recruitment
  2025-521067-13-00 5 2026-04-24 Atherosclerotic Cardiovascular Disease (ASCVD)
• Phase 3 trial aimed at improving the overall survival of AML in adults aged 18 to 60 by comparing high-dose idarubicin with daunorubicin at … Ended recruitment
  2024-516873-57-00 10 2026-01-13 Acute myeloid leukemia in adults aged 18 to 60
• MK-2870 versus Chemotherapy in Previously Treated or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other … Ended recruitment
  2023-503539-16-00 5 2025-11-11 Non-small Cell Lung Cancer (NSCLC)
• Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris … Ended recruitment
  2023-508827-10-00 4 2025-10-13 Patients with primary operable stage II, grade 2 or 3, Ki67 #20%, HR+/
• Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer Ended recruitment
  2025-521115-40-00 4 2025-09-30 Advanced or Metastatic Non-small Cell Lung Cancer
• Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLL … Ended recruitment
  2024-520050-38-00 5 2025-09-18 Extensive stage small cell lung cancer (ES-SCLC). S
• A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease Ended recruitment
  2024-519746-70-01 4 2025-09-15 Sickle Cell Disease
• A clinical study of tulisokibart in people with hidradenitis suppurativa (MK-7240-012) Ended recruitment
  2024-520039-33-00 10 2025-08-11 Hidradenitis Suppurativa
• A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended recruitment
  2024-519773-19-00 5 2025-07-31 Gastroesophageal Junction Adenocarcinoma
• A Trial of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) Ended recruitment
  2024-519095-66-00 5 2025-07-23 Kidney Transplant Recipients with Late Antibody-Mediated Rejection
• Study of Zelenectide Pevedotin in Participants with Advanced Breast Cancer Ended recruitment
  2024-517868-33-00 4 2025-06-12 NECTIN4 Amplified Advanced Breast Cancer
• Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors Ended recruitment
  2024-513307-13-00 4 2025-05-26 Advanced/metastatic solid tumors including gynecological cancers (endo
• First trial in humans testing the safety and efficacy of IMGN151 in women with recurrent gynaecological cancers Ended recruitment
  2023-506842-22-00 7 2025-05-19 Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian

Showing 457–480 of 875 trials